ALTERITY THERAPEUTICS LIMITED - Announcements

Market Cap $31.47M Add to my watchlist

Healthcare Biotechnology

Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company.... Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company’s lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson’s disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. ATH434 has been granted Orphan designation for the treatment of MSA. The Phase 2 clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA.More

Announcements

Filter Results

All Price Sensitive Only

ATH	Alterity receives a $4.74 million R&D Tax Refund	PRICE SENSITIVE	15/08/23	127.26KB	Share
ATH	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/07/23	410.71KB	Share
ATH	Ph 2 Data Monitoring Committee Recommends Continuing Trial	PRICE SENSITIVE	26/07/23	203.82KB	Share
ATH	Investor Presentation	PRICE SENSITIVE	22/06/23	3.94MB	Share
ATH	ATH to present at MST Rare Diseases Rich Returns Forum		21/06/23	132.53KB	Share
ATH	ATH starts 2nd Phase 2 Study in Rare Parkinsonian Disorder	PRICE SENSITIVE	30/05/23	202.75KB	Share
ATH	First Patient Enrolled in Australia in global Phase 2 Trial		10/05/23	203.13KB	Share
ATH	Appendix 4C and Quarterly Cash Flow Report	PRICE SENSITIVE	27/04/23	543.38KB	Share
ATH	bioMUSE Wearable Sensor Data presented at AAN Annual Meeting		26/04/23	209.58KB	Share
ATH	Notification of cessation of securities - ATH		11/04/23	21.68KB	Share
ATH	First Patient Enrolled in UK in Phase II Clinical Trial		04/04/23	201.68KB	Share
ATH	Change in substantial holding		17/03/23	1.56MB	Share
ATH	Notice Under Section 708A		16/03/23	90.41KB	Share
ATH	Application for quotation of securities - ATH		16/03/23	24.7KB	Share
ATH	First Patient Enrolled in USA in Phase II Clinical Trial		16/03/23	203.08KB	Share
ATH	Proposed issue of securities - ATH		15/03/23	24.65KB	Share
ATH	US patent grant and license agreement	PRICE SENSITIVE	14/03/23	202.1KB	Share
ATH	Investor Webinar Presentation		09/03/23	173.25KB	Share
ATH	First Patient Enrolled in Europe in Phase II Clinical trial	PRICE SENSITIVE	08/03/23	202.44KB	Share
ATH	Half Yearly Report and Accounts	PRICE SENSITIVE	28/02/23	838.3KB	Share
ATH	Regulatory approval for Phase II trial in France and Austria	PRICE SENSITIVE	16/02/23	203.83KB	Share
ATH	Change in substantial holding		15/02/23	1.45MB	Share
ATH	Notification of cessation of securities - ATH		01/02/23	21.62KB	Share
ATH	Appendix 4C and Quarterly Cash Flow Report	PRICE SENSITIVE	31/01/23	587.2KB	Share
ATH	ATH434 Prevents Brain Cell loss in Parkinsons Animal Model		30/01/23	250.29KB	Share
ATH	ATH434 Clinical Trial Launched in Italy	PRICE SENSITIVE	25/01/23	222.39KB	Share
ATH	ATH434 clinical trial launched in the US	PRICE SENSITIVE	09/01/23	224.03KB	Share
ATH	ADS ratio change		06/01/23	192.04KB	Share
ATH	Alterity to participate in Sachs Neuroscience Conference		03/01/23	170.22KB	Share
ATH	New US patent for compounds to treat neurodegeneration	PRICE SENSITIVE	29/12/22	200.25KB	Share
ATH	Change of Director's Interest Notice x 4		15/12/22	295.09KB	Share
ATH	Notification of cessation of securities - ATH		15/12/22	21.65KB	Share
ATH	Change in substantial holding		14/12/22	1.52MB	Share
ATH	ATH Constitution (amended)		16/11/22	444.95KB	Share
ATH	Results of Annual General Meeting		11/11/22	240.26KB	Share
ATH	Chairman's Address 2022 Annual General Meeting		11/11/22	313.92KB	Share
ATH	ATH Annual General Meeting Presentation		11/11/22	2.3MB	Share
ATH	Presentation of bioMUSE urinary symptom profile data		07/11/22	201.07KB	Share
ATH	Change in substantial holding		04/11/22	1.52MB	Share
ATH	Change in substantial holding		01/11/22	130.37KB	Share
ATH	Appendix 4C and Quarterly Cash Flow Report	PRICE SENSITIVE	28/10/22	661.29KB	Share
ATH	Presentation of bioMUSE MRI data		26/10/22	199.59KB	Share
ATH	ATH434 Clinical Trial launched in Australia	PRICE SENSITIVE	13/10/22	221.72KB	Share
ATH	Notice of Annual General Meeting/Proxy Form		13/10/22	607.21KB	Share
ATH	Change in substantial holding		28/09/22	1.51MB	Share
ATH	Wearable Sensor Data from bioMUSE Natural History Study		26/09/22	276.76KB	Share
ATH	Notice Under Section 708A		23/09/22	106.99KB	Share
ATH	Application for quotation of securities - ATH		23/09/22	24.74KB	Share
ATH	Proposed issue of securities - ATH		21/09/22	24.47KB	Share
ATH	US FDA Approval for IND Application for ATH434 for MSA	PRICE SENSITIVE	20/09/22	214.31KB	Share
ATH	Alterity Form 20-F and XBRL data filed with SEC		01/09/22	201.41KB	Share
ATH	Appendix 4G and Corporate Governance Statement 2022		31/08/22	390.12KB	Share
ATH	Appendix 4E & Annual Report 2022	PRICE SENSITIVE	31/08/22	1.7MB	Share
ATH	Change in substantial holding		26/08/22	353.87KB	Share
ATH	ATH434 Phase 2 clinical launched in Europe	PRICE SENSITIVE	25/08/22	220.13KB	Share
ATH	Extension to regain NASDAQ minimum bid price compliance		24/08/22	197.19KB	Share
ATH	Change in substantial holding		02/08/22	305.59KB	Share
ATH	Appendix 4C and Quarterly Cash Flow Report	PRICE SENSITIVE	22/07/22	698.61KB	Share
ATH	Change in substantial holding		20/07/22	190.5KB	Share
ATH	First Patient dosed in ATH434 Phase 2 Clinical Trial	PRICE SENSITIVE	06/07/22	202.37KB	Share
ATH	Alterity receives a $4.1 million R&D Tax Refund	PRICE SENSITIVE	30/06/22	97.77KB	Share
ATH	Notification of cessation of securities - ATH		27/06/22	21.67KB	Share
ATH	Regulatory Approval to Proceed with Phase 2 Trial in Italy	PRICE SENSITIVE	23/06/22	201.49KB	Share
ATH	Alterity to Present at Life Sciences Investor Forum		20/06/22	137.17KB	Share
ATH	Alterity to present at GCFF Virtual Conference 2022		14/06/22	158.55KB	Share
ATH	Alterity Launches ATH434 Phase 2 Clinical Trial	PRICE SENSITIVE	02/06/22	248.75KB	Share
ATH	Alterity to Participate in the Benchmark Company Conference		26/05/22	156.3KB	Share
ATH	Change in substantial holding		04/05/22	855.23KB	Share
ATH	Appendix 4C and Quarterly Cash Flow Report	PRICE SENSITIVE	29/04/22	1.38MB	Share
ATH	UK Regulatory Authorisation to Proceed with Phase 2 Trial	PRICE SENSITIVE	27/04/22	226.1KB	Share
ATH	Presentation of bioMUSE Data at the AAN Annual Meeting		07/04/22	255.02KB	Share
ATH	Change in substantial holding		22/03/22	3.07MB	Share
ATH	Change in substantial holding		17/03/22	830.04KB	Share
ATH	Alterity to participate in Sachs Neuroscience Conference		15/03/22	157.31KB	Share
ATH	Investor Presentation	PRICE SENSITIVE	07/03/22	4.98MB	Share
ATH	Alterity to Present at the 34th Annual Roth Conference		07/03/22	156.94KB	Share
ATH	NASDAQ Non-Compliance Notice Received		01/03/22	219.15KB	Share
ATH	Half Yearly Report and Accounts	PRICE SENSITIVE	28/02/22	387.79KB	Share
ATH	New publication shows ATH434 rescues neurons in MSA model	PRICE SENSITIVE	28/01/22	270.75KB	Share
ATH	Appendix 4C and Quarterly Cash Flow Report	PRICE SENSITIVE	27/01/22	421.77KB	Share
ATH	Change in substantial holding		24/01/22	853.47KB	Share
ATH	Response to ASX Query	PRICE SENSITIVE	13/01/22	217.88KB	Share
ATH	Change in substantial holding		07/01/22	1.06MB	Share
ATH	New US Patent for Compounds to Treat Neurodegeneration	PRICE SENSITIVE	06/01/22	272.5KB	Share
ATH	Alterity to present at H.C. Wainwright Conference		05/01/22	196.52KB	Share
ATH	Final Director's Interest Notice x 2		05/01/22	282.77KB	Share
ATH	Notification of cessation of securities - ATH		05/01/22	21.69KB	Share
ATH	Alterity announces resignation of Non-Executive Directors		04/01/22	182.75KB	Share
ATH	Change in substantial holding		22/12/21	891.71KB	Share
ATH	Notification of cessation of securities - ATH		15/12/21	21.68KB	Share
ATH	First Regulatory Authorization to Proceed with Phase 2 Trial	PRICE SENSITIVE	14/12/21	251.98KB	Share
ATH	Notification regarding unquoted securities - ATH		09/12/21	35.86KB	Share
ATH	Change in substantial holding		06/12/21	828.83KB	Share
ATH	Change in substantial holding		24/11/21	849.3KB	Share
ATH	Alterity to present at upcoming investor conferences		22/11/21	157.45KB	Share
ATH	Results of Annual General Meeting		12/11/21	180.09KB	Share
ATH	ATH Annual General Meeting Presentation	PRICE SENSITIVE	12/11/21	3.45MB	Share
ATH	Chairman's Address 2021 Annual General Meeting	PRICE SENSITIVE	12/11/21	200.85KB	Share
ATH	Alterity presents at American Autonomic Society Meeting		09/11/21	273.09KB	Share
ATH	New Data Advance ATH434 as Neurodegeneration treatment	PRICE SENSITIVE	04/11/21	262.43KB	Share

ATH Alterity receives a $4.74 million R&D Tax Refund
15/08/23	PRICE SENSITIVE	127.26KB	Share
ATH Quarterly Activities/Appendix 4C Cash Flow Report
31/07/23	PRICE SENSITIVE	410.71KB	Share
ATH Ph 2 Data Monitoring Committee Recommends Continuing Trial
26/07/23	PRICE SENSITIVE	203.82KB	Share
ATH Investor Presentation
22/06/23	PRICE SENSITIVE	3.94MB	Share
ATH ATH to present at MST Rare Diseases Rich Returns Forum
21/06/23		132.53KB	Share
ATH ATH starts 2nd Phase 2 Study in Rare Parkinsonian Disorder
30/05/23	PRICE SENSITIVE	202.75KB	Share
ATH First Patient Enrolled in Australia in global Phase 2 Trial
10/05/23		203.13KB	Share
ATH Appendix 4C and Quarterly Cash Flow Report
27/04/23	PRICE SENSITIVE	543.38KB	Share
ATH bioMUSE Wearable Sensor Data presented at AAN Annual Meeting
26/04/23		209.58KB	Share
ATH Notification of cessation of securities - ATH
11/04/23		21.68KB	Share
ATH First Patient Enrolled in UK in Phase II Clinical Trial
04/04/23		201.68KB	Share
ATH Change in substantial holding
17/03/23		1.56MB	Share
ATH Notice Under Section 708A
16/03/23		90.41KB	Share
ATH Application for quotation of securities - ATH
16/03/23		24.7KB	Share
ATH First Patient Enrolled in USA in Phase II Clinical Trial
16/03/23		203.08KB	Share
ATH Proposed issue of securities - ATH
15/03/23		24.65KB	Share
ATH US patent grant and license agreement
14/03/23	PRICE SENSITIVE	202.1KB	Share
ATH Investor Webinar Presentation
09/03/23		173.25KB	Share
ATH First Patient Enrolled in Europe in Phase II Clinical trial
08/03/23	PRICE SENSITIVE	202.44KB	Share
ATH Half Yearly Report and Accounts
28/02/23	PRICE SENSITIVE	838.3KB	Share
ATH Regulatory approval for Phase II trial in France and Austria
16/02/23	PRICE SENSITIVE	203.83KB	Share
ATH Change in substantial holding
15/02/23		1.45MB	Share
ATH Notification of cessation of securities - ATH
01/02/23		21.62KB	Share
ATH Appendix 4C and Quarterly Cash Flow Report
31/01/23	PRICE SENSITIVE	587.2KB	Share
ATH ATH434 Prevents Brain Cell loss in Parkinsons Animal Model
30/01/23		250.29KB	Share
ATH ATH434 Clinical Trial Launched in Italy
25/01/23	PRICE SENSITIVE	222.39KB	Share
ATH ATH434 clinical trial launched in the US
09/01/23	PRICE SENSITIVE	224.03KB	Share
ATH ADS ratio change
06/01/23		192.04KB	Share
ATH Alterity to participate in Sachs Neuroscience Conference
03/01/23		170.22KB	Share
ATH New US patent for compounds to treat neurodegeneration
29/12/22	PRICE SENSITIVE	200.25KB	Share
ATH Change of Director's Interest Notice x 4
15/12/22		295.09KB	Share
ATH Notification of cessation of securities - ATH
15/12/22		21.65KB	Share
ATH Change in substantial holding
14/12/22		1.52MB	Share
ATH ATH Constitution (amended)
16/11/22		444.95KB	Share
ATH Results of Annual General Meeting
11/11/22		240.26KB	Share
ATH Chairman's Address 2022 Annual General Meeting
11/11/22		313.92KB	Share
ATH ATH Annual General Meeting Presentation
11/11/22		2.3MB	Share
ATH Presentation of bioMUSE urinary symptom profile data
07/11/22		201.07KB	Share
ATH Change in substantial holding
04/11/22		1.52MB	Share
ATH Change in substantial holding
01/11/22		130.37KB	Share
ATH Appendix 4C and Quarterly Cash Flow Report
28/10/22	PRICE SENSITIVE	661.29KB	Share
ATH Presentation of bioMUSE MRI data
26/10/22		199.59KB	Share
ATH ATH434 Clinical Trial launched in Australia
13/10/22	PRICE SENSITIVE	221.72KB	Share
ATH Notice of Annual General Meeting/Proxy Form
13/10/22		607.21KB	Share
ATH Change in substantial holding
28/09/22		1.51MB	Share
ATH Wearable Sensor Data from bioMUSE Natural History Study
26/09/22		276.76KB	Share
ATH Notice Under Section 708A
23/09/22		106.99KB	Share
ATH Application for quotation of securities - ATH
23/09/22		24.74KB	Share
ATH Proposed issue of securities - ATH
21/09/22		24.47KB	Share
ATH US FDA Approval for IND Application for ATH434 for MSA
20/09/22	PRICE SENSITIVE	214.31KB	Share
ATH Alterity Form 20-F and XBRL data filed with SEC
01/09/22		201.41KB	Share
ATH Appendix 4G and Corporate Governance Statement 2022
31/08/22		390.12KB	Share
ATH Appendix 4E & Annual Report 2022
31/08/22	PRICE SENSITIVE	1.7MB	Share
ATH Change in substantial holding
26/08/22		353.87KB	Share
ATH ATH434 Phase 2 clinical launched in Europe
25/08/22	PRICE SENSITIVE	220.13KB	Share
ATH Extension to regain NASDAQ minimum bid price compliance
24/08/22		197.19KB	Share
ATH Change in substantial holding
02/08/22		305.59KB	Share
ATH Appendix 4C and Quarterly Cash Flow Report
22/07/22	PRICE SENSITIVE	698.61KB	Share
ATH Change in substantial holding
20/07/22		190.5KB	Share
ATH First Patient dosed in ATH434 Phase 2 Clinical Trial
06/07/22	PRICE SENSITIVE	202.37KB	Share
ATH Alterity receives a $4.1 million R&D Tax Refund
30/06/22	PRICE SENSITIVE	97.77KB	Share
ATH Notification of cessation of securities - ATH
27/06/22		21.67KB	Share
ATH Regulatory Approval to Proceed with Phase 2 Trial in Italy
23/06/22	PRICE SENSITIVE	201.49KB	Share
ATH Alterity to Present at Life Sciences Investor Forum
20/06/22		137.17KB	Share
ATH Alterity to present at GCFF Virtual Conference 2022
14/06/22		158.55KB	Share
ATH Alterity Launches ATH434 Phase 2 Clinical Trial
02/06/22	PRICE SENSITIVE	248.75KB	Share
ATH Alterity to Participate in the Benchmark Company Conference
26/05/22		156.3KB	Share
ATH Change in substantial holding
04/05/22		855.23KB	Share
ATH Appendix 4C and Quarterly Cash Flow Report
29/04/22	PRICE SENSITIVE	1.38MB	Share
ATH UK Regulatory Authorisation to Proceed with Phase 2 Trial
27/04/22	PRICE SENSITIVE	226.1KB	Share
ATH Presentation of bioMUSE Data at the AAN Annual Meeting
07/04/22		255.02KB	Share
ATH Change in substantial holding
22/03/22		3.07MB	Share
ATH Change in substantial holding
17/03/22		830.04KB	Share
ATH Alterity to participate in Sachs Neuroscience Conference
15/03/22		157.31KB	Share
ATH Investor Presentation
07/03/22	PRICE SENSITIVE	4.98MB	Share
ATH Alterity to Present at the 34th Annual Roth Conference
07/03/22		156.94KB	Share
ATH NASDAQ Non-Compliance Notice Received
01/03/22		219.15KB	Share
ATH Half Yearly Report and Accounts
28/02/22	PRICE SENSITIVE	387.79KB	Share
ATH New publication shows ATH434 rescues neurons in MSA model
28/01/22	PRICE SENSITIVE	270.75KB	Share
ATH Appendix 4C and Quarterly Cash Flow Report
27/01/22	PRICE SENSITIVE	421.77KB	Share
ATH Change in substantial holding
24/01/22		853.47KB	Share
ATH Response to ASX Query
13/01/22	PRICE SENSITIVE	217.88KB	Share
ATH Change in substantial holding
07/01/22		1.06MB	Share
ATH New US Patent for Compounds to Treat Neurodegeneration
06/01/22	PRICE SENSITIVE	272.5KB	Share
ATH Alterity to present at H.C. Wainwright Conference
05/01/22		196.52KB	Share
ATH Final Director's Interest Notice x 2
05/01/22		282.77KB	Share
ATH Notification of cessation of securities - ATH
05/01/22		21.69KB	Share
ATH Alterity announces resignation of Non-Executive Directors
04/01/22		182.75KB	Share
ATH Change in substantial holding
22/12/21		891.71KB	Share
ATH Notification of cessation of securities - ATH
15/12/21		21.68KB	Share
ATH First Regulatory Authorization to Proceed with Phase 2 Trial
14/12/21	PRICE SENSITIVE	251.98KB	Share
ATH Notification regarding unquoted securities - ATH
09/12/21		35.86KB	Share
ATH Change in substantial holding
06/12/21		828.83KB	Share
ATH Change in substantial holding
24/11/21		849.3KB	Share
ATH Alterity to present at upcoming investor conferences
22/11/21		157.45KB	Share
ATH Results of Annual General Meeting
12/11/21		180.09KB	Share
ATH ATH Annual General Meeting Presentation
12/11/21	PRICE SENSITIVE	3.45MB	Share
ATH Chairman's Address 2021 Annual General Meeting
12/11/21	PRICE SENSITIVE	200.85KB	Share
ATH Alterity presents at American Autonomic Society Meeting
09/11/21		273.09KB	Share
ATH New Data Advance ATH434 as Neurodegeneration treatment
04/11/21	PRICE SENSITIVE	262.43KB	Share

REFRESH

First 2 3 4 5 6

(20min delay)
Last 0.6¢		Change 0.000(0.00%)		Mkt cap ! $31.47M

Open	High	Low	Value	Volume
0.6¢	0.6¢	0.6¢	$9.373K	1.599M

Buyers (Bids)

No.	Vol.	Price($)
72	66652678	0.5¢

Sellers (Offers)

Price($)	Vol.	No.
0.6¢	6250837	4

View Market Depth

No.	Vol.	Price($)
72	66652678	0.005
53	59859382	0.004
49	47623315	0.003
17	33693014	0.002
12	93870101	0.001

Price($)	Vol.	No.
0.006	6250837	4
0.007	21612749	17
0.008	20271032	23
0.009	11788078	12
0.010	2540594	8

Last trade - 13.01pm 08/05/2024 (20 minute delay)


Last 0.6¢		Change 0.000 ( 0.00 %)
Open	High	Low	Volume
0.6¢	0.6¢	0.6¢	361890
Last updated 13.49pm 08/05/2024 ?

ATH (ASX) Chart

ALTERITY THERAPEUTICS LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories